Treatment with Ultomiris (ravulizumab) safely helps maintain or achieve disease control in people with paroxysmal nocturnal hemoglobinuria (PNH), according to a real-world study involving more than 200 adults. Among that group, people who switched from the older therapy, Soliris (eculizumab), to…
Discussion
Note: This column describes the author’s experiences with Fabhalta (iptacopan). Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. There’s something powerful about being able to say, “This is getting better.” After the uncertainty that came with my recent medication change for…
The first patient has been dosed in Argo Biopharmaceutical’s Phase 2 clinical trial of BW-40202 for paroxysmal nocturnal hemoglobinuria (PNH), one of two new Phase 2 studies testing the investigational therapy. The Phase 2 studies follow a Phase 1 trial (NCT06917482) initiated last year to assess BW-40202’s…
Doctors in China diagnosed a man with paroxysmal nocturnal hemoglobinuria (PNH) after a biopsy and specialized MRI, performed to assess kidney problems, yielded clues about ongoing red blood cell breakdown. The tests identified iron buildup in the man’s kidneys (renal hemosiderosis). The findings raised suspicion of ongoing red blood…
Get regular updates delivered to your inbox.
